4 results about "Rifamycins" patented technology

This invention relates to novel uses of pharmaceuticals, particularly the use of rifamycin in the preparation of medicaments for treating colorectal cancer. The application described herein involves rifamycin stabilizing the binding of DHRS4 and LONP2 within the mitochondria of colorectal cancer cells, promoting TFAM degradation, thereby impairing mitochondrial biogenesis and function, and inhibiting mitochondrial activity. In this application, rifamycin is either the sole active ingredient or used in combination with other drugs.

This invention discloses a method for preparing rifamycin O, an intermediate of rifaximin, in the field of organic synthesis. The method uses rifamycin B as a starting material, and rifamycin O is obtained by oxidative coupling under the action of a solvent and a catalyst; the catalyst is a FeCl3 / Al2O3 solid oxidant. This invention uses FeCl3 / Al2O3 solid oxidant to oxidize rifamycin B to prepare rifamycin O. The oxidative coupling reaction conditions are mild, the post-processing is simple, the process cycle is short, and the yield and product purity are high, making it suitable for industrial production.

The invention relates to a new topical nasal pharmaceutical composition for the treatment and prophylaxis of Rhinosinusitis (RS), comprising a homogeneous aqueous suspension with a therapeutically effective amount of the following well-known active ingredients: Rifamycin, an antibiotic and anti-inflammatory agent for topical or local use; fluticasone propionate, an anti-inflammatory agent for local use; optionally, oxymetazoline hydrochloride, a decongestant; and bacterial antigens, local immunostimulants; 0.9% saline solution, a vehicle; and pharmaceutically acceptable excipients q.s., which are formulated for topical administration via nasal spray. The combination of these compounds produces synergy, resulting in a greater local antibiotic, anti-inflammatory, decongestant and immunomodulatory effect at the specific site of action. Its effectiveness in chronic rhinosinusitis is particularly notable in low doses. So is its good tolerance, absence of adverse effects, and ease of application. No rebound congestion has been reported with prolonged use.

The present disclosure relates to compositions comprising rifamycin SV and their use in the treatment of sarcopenia. More specifically, the present disclosure describes pharmaceutical compositions comprising rifamycin SV for use in the treatment of sarcopenia in a subject suffering from a chronic disease.